)
Visual
test
Blueprint Medicines
Blueprint Medicines (BPMC) investor relations material
Blueprint Medicines has been acquired
Blueprint Medicines The Citizens JMP Life Sciences Conference 2025 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.The Citizens JMP Life Sciences Conference 2025 summary7 May, 2025
Company overview and strategic focus
Focused on developing life-changing medicines for diseases related to mast cell biology, evolving from an oncology heritage.
Lead product AYVAKIT treats systemic mastocytosis (SM), a rare disease caused by a mast cell mutation.
Pipeline includes programs targeting wild-type mast cells for type 2 inflammatory diseases.
Strong financial position, aiming for self-sustainability and continued growth.
AYVAKIT commercial performance and market opportunity
Approved in three indications: a GIST subtype, advanced SM, and indolent SM (ISM), with ISM being the largest market.
ISM approval in mid-2023 opened a significant growth opportunity, with an estimated 60,000 US patients, 90-95% of whom have ISM.
2025 revenue guidance is $700–$720 million, with a target of $2 billion in global revenue by 2030.
Franchise opportunity projected at $4 billion+, with the US expected to contribute 70–80% at peak.
Market penetration and growth strategies
Achieving $2 billion revenue by 2030 requires treating only a minority of diagnosed patients, about 6,000 in the US.
Focus on expanding prescriber experience and direct-to-consumer digital engagement to drive patient demand.
Recurring revenue base supported by long therapy duration, with patients modeled to stay on treatment for three or more years.
Sophisticated data operations and targeted sales efforts prioritize high-need patient locations.
Prioritize diagnosed vs. new ISM patient ID?
BLU-808: What's its role in type 2 treatment?
Discovery output: How to leverage excess innovation?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- GL
Earnings and sales grew across all segments, with higher 2026 guidance and ongoing share buybacks. - RSI
Record financial results, all motions passed, and LEAP project remains a strategic priority. - COST
January sales climbed 9.3% to $21.33B, with digital sales up 34.4%. - FR
FFO per share rose 11.7% in 2025, with robust rental growth and a higher dividend. - ALCO
Land sales and leasing drove improved profitability and strong liquidity as citrus operations ended. - PAHC
Net sales and profit surged on acquisition, with raised outlook and strong liquidity. - PTC
Q1'26 saw double-digit growth, margin gains, and major share repurchases, with a strong FY'26 outlook. - MKL
Operating income rose to $3.2B, with broad-based growth and improved insurance profitability. - UHAL
Q3 net loss of $37M on higher costs and depreciation, but self-storage revenue increased. - SITM
Acquisition accelerates growth to $1B revenue, expanding leadership in precision timing.
Blueprint Medicines
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Blueprint Medicines Corp. is a biopharmaceutical company focused on developing targeted therapies for genomically defined cancers and rare diseases. The company utilizes precision medicine approaches to design small-molecule drugs that inhibit specific genetic drivers of disease. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage